Table 1.
Demographic characteristics and clinical features of patients with BD
| Parameter | Value |
|---|---|
| Age, mean ± SD [years] | 38.3 ±8.4 |
| Age at diagnosis, mean ± SD [years] | 30.4 ±7.6 |
| Disease duration, median (IQR) [months] | 96.3 (74.1) |
| Female/male, n (%) | 36 (38.7)/57 (61.3) |
| Active disease, n (%) | 57 (61.3) |
| BDCAF, median (IQR) | 2.0 (0.0–3.0) |
| Disease manifestations ever presented by BD patients, n (%): | |
| Oral ulcers | 93 (100) |
| Genital ulcers | 72 (77.4) |
| Erythema nodosum | 42 (45.2) |
| Papulopustular lesions | 55 (59.1) |
| Positivity of pathergy test | 20 (21.5) |
| Arthritis | 37 (39.8) |
| Uveitis | 35 (37.6) |
| Vascular involvement | 31 (33.3) |
| Gastrointestinal system involvement | 1 (1.1) |
| Central nervous system involvement | Parenchymal 7 (7.5) Cerebral venous sinus thrombosis (1.1) |
| Pulmonary aneurysm | 2 (2.2) |
| Medical therapy, n (%): | |
| Colchicine | 71 (66) |
| Azathioprine | 47 (50.5) |
| Cyclophosphamide | 3 (3.2) |
| Corticosteroids | 50 (53.8) |
| Interferon | 1 (1.1) |
| Anti-TNF | 1 (1.1) |
| No therapy | 4 (3.7) |